Chengdu University of Traditional Chinese Medicine, School of Clinical Medicine.
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Medicine (Baltimore). 2021 Jan 8;100(1):e24131. doi: 10.1097/MD.0000000000024131.
Previous review indicate that the effect of traditional Chinese medicines (TCM) on pulmonary heart disease (PHD) remains uncertainty. Therefore, we designed this study to systematically evaluate the effectiveness and safety of TCM in the treatment of PHD.
Nine online databases will be searched from inception to October 01, 2021, and we will not restrict the language on included trials. Randomized controlled trials that included patients with PHD receiving TCM therapy vs a control group will be included. Two of us will perform independently the selection of studies, risk of bias assessment, and data extraction. The RevMan V.5.2 software with fixed effects model or random effects model will be used to syntheses the data, according to the heterogeneity test to conduct the data synthesis. The dichotomous data and the continuous data will be presented with risk ratios with 95% confidence intervals and weighted mean differences or standardized mean differences with 95% confidence intervals. And we will use the Grading of Recommendations Assessment, Development, and Evaluation system to evaluate the evidence quality.
This study will assess effects and safety for TCM on PHD.
The conclusion of this study will provide evidence to prove the safety and effectiveness of TCM on PHD.
INPLASY2020120024.
既往综述表明，中药（TCM）治疗肺心病（PHD）的疗效仍存在不确定性。因此，我们设计了这项研究，旨在系统评估 TCM 治疗 PHD 的疗效和安全性。
我们将从建库至 2021 年 10 月 01 日检索 9 个在线数据库，对纳入的研究不限制语言。纳入的研究为接受 TCM 治疗的 PHD 患者与对照组的随机对照试验。我们将由 2 位研究者独立进行研究选择、偏倚风险评估和数据提取。根据异质性检验，采用固定效应模型或随机效应模型对数据进行合并。二分类数据和连续数据将采用比值比及其 95%置信区间，以及加权均数差或标准化均数差及其 95%置信区间表示。我们将采用推荐评估、制定与评价系统（Grading of Recommendations Assessment, Development, and Evaluation system）评估证据质量。
本研究将评估 TCM 治疗 PHD 的效果和安全性。
本研究的结论将为 TCM 治疗 PHD 的安全性和有效性提供证据。
INPLASY2020120024。
